Paganelli, FernandoCardillo, Jose A.Dare, Alessandro R. J.Melo, Luiz A. S.Lucena, David R.Silva, Arnobio A. [UNESP]Oliveira, Anselmo Gomes de [UNESP]Pizzolitto, Antonio Carlos [UNESP]Lavinsky, DanielSkaf, MirianSouza-Filho, Acacio A.Hofling-Lima, Ana L.Nguyen, Quan DongKuppermann, Baruch D.Herrero-Vanrell, RocioBelfort, Rubens2014-05-202014-05-202010-08-01Expert Opinion on Drug Delivery. London: Informa Healthcare, v. 7, n. 8, p. 955-965, 2010.1742-5247http://hdl.handle.net/11449/7842Importance of the field: The use of topical agents poses unique and challenging hurdles for drug delivery. Topical steroids effectively control ocular inflammation, but are associated with the well-recognized dilemma of patient compliance. Although administration of topical antimicrobials as prophylaxis is acceptable among ophthalmologists, this common practice has no sound evidence base Developing a new antimicrobial agent or delivery strategy with enhanced penetration by considering the anatomical and physiological constraints exerted by the barriers of the eye is not a commonly perceived strategy. Exploiting the permeability of the sclera, subconjunctival routes may offer a promising alternative for enhanced drug delivery and tissue targeting.Area covered in this review: Ocular drug delivery strategies were reviewed for ocular inflammation and infections clinically adopted for newer class of antimicrobials, which use a multipronged approach to limit risks of endophthalmitis.What the reader will gain: The analysis substantiates a new transscleral drug delivery therapeutic approach for cataract surgery.Take home message: A new anti-inflammatory and anti-infective paradigm that frees the patient from the nuisance of topical therapeutics is introduced, opening a large investigative avenue for future improved therapies.955-965engantibioticsantimicrobialscataract surgeryendophthalimitiseye dropseye infectionsintraocular penetrationocular drug deliveryArtigo10.1517/17425247.2010.498817WOS:000281032400006Acesso restrito9114495952533044